# NCT03314181 (NCT03314181)

> A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma

No report yet. It can be ordered.

- Drugs tested: venetoclax plus daratumumab plus dexamethasone; venetoclax plus daratumumab plus dexamethasone plus bortezomib
- Indication: relapsed or refractory multiple myeloma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03314181
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: AbbVie
- Conditions: Multiple Myeloma
- Interventions: Dexamethasone; Daratumumab; Venetoclax; Bortezomib
- Enrollment: 156
- Primary outcome: Overall Response Rate (ORR)
- Primary outcome: Very Good Partial Response or Better Response Rate (VGPR)
- Primary outcome: Complete Response (CR) or Better Rate
- Primary outcome: Time to Response (TTR)
- Primary outcome: Duration of Response (DOR)
- Primary outcome: Time to Progression (TTP)
- Primary outcome: Progression-Free Survival (PFS)
- Primary outcome: Overall Survival (OS)

## Indexed commentary on NCT03314181 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=nct03314181